POSSIBILITY OF CORRECTION OF OXIDATIVE STRESS IN PATIENTS WITH DIABETES USING DIBICOR

Currently, drugs for correcting free-radical-mediated oxidative stress (OS) are widely used in the treatment of patients with diabetes mellitus (DM). One of these drugs is Dibicor containing active substance taurine. Taurine directly affects the antioxidant system of cells through the formation of N-chlorotaurine, which inhibits superoxide radicals, reduces the production of tumor necrosis factor and peroxylnitrite, and stimulates the formation of superoxide dismutase. For the purpose of evaluation its influence on the activity of other antioxidant enzymes and content of oxidatively modified proteins (OMP), the author have examined 34 patients with type 2 diabetes mellitus (DM2). Patients were divided into two groups: one group of patients (n = 20) received Dibicor at dose of 1 g/day within 2 months against the background of basic antihyperglicemic therapy, patients of the other group (n = 14) received only the basic antihyperglicemic therapy. It was shown that use of Dibicor against the background of basic antihyperglicemic therapy led to statistically significant increase in catalase activity and decrease in different fractions of OMP. The tendency to increased levels of nitric oxide metabolites in patients treated with Dibicor was noted, that can be considered as a positive attempt to correction of endothelial dysfunction in patients with type 2 diabetes mellitus against the background of reduction of OS. Given the positive trend in the correction of endothelial dysfunction in these patients, the use of Dibicor should be prolonged.

type 2 diabetes mellitus, oxidative modification of proteins, lipid peroxidation, endothelial dysfunction, Dibicor, taurine